Nextgen Biomed Ltd. operates as a research and development company. Its primary product is Eyepen, a smart and modular device consisting of pens for injecting insulin, and helps users self-manage the treatment of diabetes by documenting the times and doses of taking insulin by injection. The company was founded on December 26, 1990 and is headquartered in Raanana, Israel.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company